Results 71 to 80 of about 7,789 (204)

Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment

open access: hybrid, 2022
Edward V. Loftus   +16 more
openalex   +1 more source

Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis   +54 more
wiley   +1 more source

Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies

open access: yesRMD Open
Introduction Patients with rheumatoid (RA) or psoriatic (PsA) arthritis can experience debilitating pain.Methods Post hoc analyses of phase 3, double-blind studies in patients with active disease despite treatment (SELECT-COMPARE, SELECT-PsA 1) assessed ...
Bruno Fautrel   +10 more
doaj   +1 more source

Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This review assessed 52 biomarkers predicting systemic therapy response and adverse events in atopic dermatitis. Most studies focused on dupilumab, and findings were inconsistent. IgE and eosinophils were largely non‐predictive, though elevated eosinophils and LDH sometimes indicated poorer outcomes.
Eva Hilger   +11 more
wiley   +1 more source

Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment

open access: yes
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 260-263, March 2025.
Celeste M. Boesjes   +7 more
wiley   +1 more source

Cutaneous T‐cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Systematic review (51 studies; 547 patients) indicates dupilumab may unmask/worsen CTCL (mainly MF/SS). A French Delphi consensus recommends rigorous diagnostic workup, avoiding dupilumab in confirmed CTCL, discontinuing upon diagnosis, and favouring methotrexate or phototherapy.
Florent Amatore   +8 more
wiley   +1 more source

Severe and disseminated atypical mycobacteriosis of the skin under immunosuppression

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Veronika Zenderowski   +6 more
wiley   +1 more source

A Case Study and Review of the Literature on IgA Nephropathy in Crohn's Disease

open access: yesClinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT IgA nephropathy (IgAN) is the most frequently reported glomerular disease associated with inflammatory bowel disease (IBD), particularly Crohn's disease (CD), although pediatric cases remain rare. We report IgAN in a 16‐year‐old male with CD following intestinal surgery and during long‐term infliximab therapy, with renal impairment occurring ...
Giovanna Fernanda Vazzana   +6 more
wiley   +1 more source

JAK inhibitors and menstrual cycle alterations: insights from a case series of 16 female patients

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Luciano Ibba   +11 more
wiley   +1 more source

Vedolizumab Induces Remission in Two Cases of Ulcerative Colitis With Upper Gastrointestinal Involvement

open access: yesDEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Ulcerative colitis (UC) predominantly affects the colon; upper gastrointestinal involvement (UGI) has been reported, but no established treatments exist. We report two cases of UC with concomitant UGI that showed positive responses to vedolizumab therapy.
Shinya Nakatani   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy